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Abstract 
Transmissible spongiform encephalopathies (scrapie, BSE, Kuru) develop as CNS 
diseases after long incubation periods, and many of which may arise following the 
consumption of infected material. The infectious agent is thought to be a mis-folded 
form (PrPSc) of a normal host protein (PrPC), which is relatively resistant to 
proteolytic degradation and which serves as a template, directing host PrP to 
accumulate in the misfolded form. Animal experiments have shown that CNS disease 
is preceded by a period in which the agent accumulates in secondary lymphoid organs 
(Peyer’s patches, lymph nodes, spleen), particularly follicular dendritic cells in the B 
cell areas of these organs. How the agent is transmitted from the intestinal lumen to 
the FDCs is largely unknown.  Dendritic cells (DCs, cells quite distinct from FDCs) 
are cells that are specialised to acquire antigens from peripheral tissues and to 
transport them to secondary lymphoid organs for presentation to T and B 
lymphocytes. We have shown that DCs can acquire PrPSc from the intestinal lumen 
and deliver it to mesenteric lymph nodes.  In this review we discuss the different 
stages involved in the migration of PrPSc from the intestine to FDCs and consider the 
different stages and barriers involved in this process. We conclude that transport of 
the causative agent, using PrPSc as a biomarker, from the intestine to FDCs is a very 
inefficient process, which may help to account for the apparent low frequency of 
individuals who have consumed infected material that go on to develop clinical 
disease. 
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1. Introduction: Prions and the oral transmission of TSE 
 
The oral route of infection has been implicated in the pathogenesis of transmissible 
spongiform encephalopathy (TSE), a disease that targets clinically the central nervous 
system (CNS). Spread of the disease, both naturally and experimentally, by ingestion 
of the infectious agent has been described in a variety of species ranging from 
domestic, as well as wild-life, animals to man [1-10]. The likelihood of spread of the 
bovine form of TSE (BSE) [11] to human (nvCJD) through the food-chain [6] has 
aroused long-lasting public health anxiety with adverse economical and political 
consequences, both in the UK and abroad for the last decade [12-14]. Due to the long 
incubation period of the illness, infected individuals may remain asymptomatic for 
years.  It remains still highly uncertain as to how risky it has been, or how safe it is 
now, to eat beef or even meat from other animals likely to carry and pass on the 
mysterious ‘mad cow’ disease [7, 15].   
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The disease has also led to the proposition of a novel mechanism of infectivity: that is 
an infectious agent (TSEA) possibly devoid of nucleic acid. This was first indicated 
by its refractoriness to UV irradiation [16]. It is also complicated by the many other 
unusual physical and biological properties of the molecules including, most 
worryingly, its extraordinary resistance to conventional sterilization procedures. The 
exact nature of the etiologic agent has been, and still is, a focus of scientific debate. 
Although the possible causal agent being an “unconventional slow virus” (Virino 
Theory) [17] is not excluded [18], live virus of this kind has not been isolated. The 
lack of specific immune response to the puzzling agent [19], and the absence of 
inflammatory cell infiltrate in the affected brains, seem to suggest otherwise [20, 21].  
 
PrPSc, also known as ‘scrapie-associated prion protein’, is an abnormally folded, self-
encoded protein (PrPC) that co-purifies with TSE infectivity [22, 23]. The molecule is 
now considered to be the crucial, if not the only agent (Protein Theory), responsible 
for the infection [24]. Structurally, PrPSc is rich in β-sheets, in contrast to the α-helix-
rich PrPC, and is insoluble in many detergents. The current hypothesis suggests that 
the pathogenesis involves a key step of prion protein conversion and replication in 
which PrPSc converts the normal protein, PrPC, into the abnormal form [25]. The agent 
replicates in this way by a post-translational alteration of the tertiary structure 
(conformational change), but not amino acid sequence, of the host-encoded protein, 
turning it into a highly self-aggregating, protease-resistant pathological isoform [26, 
27]. The “Protein only” theory [28, 29] is supported by evidence from transgenic and 
knockout studies that mice devoid of PrP (Prnp-/-) are totally resistant to the disease 
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[30], although it is not impossible that the protein is an intermediate yet indispensable 
molecule merely mediating neuropathology [18]. 
 
2. The immune system in prion diseases 
 
A long incubation period preceding the neurological symptoms is common to all 
TSEs. Much evidence indicates that TSEA replication as described above is essential 
for the development of clinical disease and that such replication occurs, at least 
primarily, in the immune system.  
 
In spite of the lack of any signs of an immune response, it has been known for a long 
that the immune system plays a crucial role in TSE pathogenesis [31]. Splenectomy of 
mice before infection significantly prolongs the incubation period of the disease after 
peripheral inoculation [32, 33], as does genetic asplenia [34], but athymia and 
neonatal thymectomy have no effect [33]. Severe combined immunodeficient (SCID) 
mice lacking mature T and B lymphocytes fail to develop the disease [32], but 
become susceptible after reconstitution with normal splenocytes [35]. 
Immunosuppressive drugs can prolong the incubation time of the disease [36], 
whereas stimulation of the lymphoid systems with mitogens enhances disease 
susceptibility [37].  
 
Following peripheral infection, PrPSc is detected in the spleen, lymph nodes and other 
lymphoid tissues long before CNS involvement [38-40]. The spleen however may not 
be the main organ involved in infection via the oral route, infectivity being found first 
in the Peyer’s patches [39]. This suggests that the gut-associated lymphoid tissues 
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(GALT) may serve a similar processing and replicative function for intestinally-
routed inocula. Early accumulation of PrPSc in GALT, including mesenteric nodes, 
has also been described in sheep with scrapie, a natural TSE infection. At a later stage 
and to a lesser extent, the agent spreads to other systemic or non-gut-associated 
lymphoid tissues including the spleen [41-44]. Interestingly splenic PrPSc 
accumulation is not detectable in cows naturally infected with BSE [45], but is 
evident in experimental animal models including BSE-infected mice[46] and sheep 
[47].  
 
Thus peripheral lymphoid organs are important and perhaps indispensable in the 
transmission and development of the neurodegenerative disease. It is now believed 
that in most infectious forms of TSE, not only must the infectious agent transit 
through, but also replicate in the lymphoreticular compartment before invading the 
central nervous system [31]. Kaeser and colleagues showed recently that optimal 
prion replication requires PrPC expression by both stromal and haematopoietic 
compartments [48]. The questions then become: (1) what cell type(s) in the lymphoid 
organs that may support replication and propagation of prions; and (2) how exactly do 
these infectious proteins travel from their sites of penetration (e.g. gut) to sites of 
replication (lymphoid organs) thence into the CNS. A good understanding of these 
processes is obviously very important in early diagnosis as well as the development of 
new strategies for treatment and even prevention of the disease. 
 
3. Follicular dendritic cells as the site for prion propagation 
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The cell type(s) likely to be involved in propagation of prions are thought to be of low 
density [49], long-lived and mitotically quiescent cells [50]. Follicular dendritic cells 
(FDCs) in the germinal centres of lymphoid organs or tissues display all these 
characteristics, and they are also strong PrP-expressing cells [51]. They have been 
long suspected to be the main cell type targeted by the TSE agents. In studies by 
many different groups, FDCs [31, 43, 51-53] as well as some macrophages or 
macrophage-like cells [41, 43, 54, 55] are reported to be sites of PrPSc accumulation 
soon after peripheral infection. It has been suggested that FDCs can capture prions 
through their complement receptors [56, 57], a similar cellular interaction described 
previously for the retention of HIV viruses by the cells [58]. The cell-free conversion 
of PrPC to PrPSc in the presence of PrPSc [59] suggests it is also possible that PrP may 
act as an autoligand. 
 
Based on findings from several genetically modified mouse models, however, other 
groups of investigators argued that B cells [60], and possibly other unidentified cells 
[61], might be also crucial in peripheral prion transmission. The authors demonstrated 
that mice devoid of B, but not T, cells were resistant to disease inoculation via 
peripheral routes, while the animals remained equally sensitive to infection by 
intracerebral injection [62]. The same group reported subsequently that PrP 
expression in B lymphocytes was not required for prion neuroinvasion, since 
immunological constitution with haematopoietic precursors from PrP knock-out 
donors restored sensitivity to disease induction [60]. One explanation may be that B 
cells are not directly involved in replication but rather transport of the agents. 
Alternatively, the lack of B cells or B cell products may prevent FDC maturation and 
differentiation [63, 64]. By using chimeric mouse models mismatched in PrP status 
 9 
between FDCs and other cells of the immune system, Brown and colleagues showed 
that replication of prions in the spleen depends on PrP-expressing FDCs rather than 
on lymphocytes or other bone marrow-derived cells, and that the contribution of B 
cells is related to their ability to induce the functional maturation of FDCs [65]. The 
role of FDCs in TSE pathogenesis, at least acting as the primary sites for prion 
replication, is once again emphasized and largely comfirmed. 
 
4. Entry and transport of orally-acquired TSEA 
 
An important question is how do FDCs acquire TSE agents following intestinal 
delivery, since FDCs are resident cells in B-cell follicles of organized lymphoid 
tissues (i.e. not peripheral tissues). TSE agents must first cross the intestinal epithelial 
barrier and be transported via lymphatics to the draining mesenteric nodes, or via the 
blood stream to the spleen (which lacks afferent lymphatic drainage). Transport of 
whole proteins or particles across intact epithelium is very inefficient. Thus it seems 
unlikely that passive transport across the epithelium and random distribution via the 
blood or lymph would suffice to deliver sufficient infective material to the lymphoid 
organs to initiate an infection.  
 
Intestinal epithelium consists of a continuous sheet with individual cells joined by 
tight junctions. It forms an effective barrier to the movement of molecules and 
particles into the underlying connective tissues. The seal is however by no means 
complete, and it is possible that small amounts of macromolecules do transverse the 
epithelial barrier by transcytosis. In Peyer’s patches and intestinal lymphoid follicles, 
the overlying epithelium is specialized to facilitate the transport of macromolecules 
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and particles, and their delivery to lymphocytes and antigen presenting cells (APC) 
including DC. This transport is mediated by M cells, specialized epithelial cells that 
have poorly developed microvilli and that are able to rapidly transcytose tracers such 
as horse-radish peroxidase and fluorescent latex particles to the subjacent areas of the 
patch [66]. The ability of M cells to transport particles and macromolecules has been 
‘hi-jacked’ by a number of intestinal pathogens to enable them to across the epithelia 
barrier [67-72].  
 
5. Migrating intestinal dendritic cells transport PrPSc from the gut 
 
It is important not to confuse follicular DC with the ‘conventional’ DC also known as 
the ‘Steinman’ DC [73, 74]. As compared in Table 1, the two types of cells share 
almost nothing except their ‘dendritic’ morphology. FDCs are long-lived cells that 
retain immune complexes on their surface for years and present them to B cells [75]. 
They are probably not haematopoietic. In contrast the ‘Steinman’ DC is a short-lived 
bone-marrow-derived cell found both in peripheral tissues and in the T cell areas of 
lymphoid organs. In peripheral tissues, they are actively endocytic [76] and in some 
circumstances are macropinocytotic, facilitating uptake of large amount of solutes and 
small particles [77]. The main function of these cells is to acquire antigens in 
peripheral tissues and transport them, via draining lymphatics, to secondary lymphoid 
organs [78]. DCs present processed antigen, as small peptides in association with 
MHC molecules, primarily to T cells, although they can also present intact antigens to 
B cells [79]. Some DCs are found to express the normal PrP protein [80, 81]. 
Importantly, unlike FDCs, DCs are actively migratory. 
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Intestinal DCs are bone marrow-derived cells of the ‘conventional’ DC type, which 
migrate from the intestinal wall to draining mesenteric nodes. The area of PP 
underlying the dome is rich in DCs, macrophages and lymphocytes [82, 83]. DCs 
have also been described in the lamina propria (LP) [84]. Unlike tissue macrophages 
[85], DCs spend only a short time (2-4 days) in the intestinal wall, and migrate 
continuously to mesenteric lymph nodes via lymph. They have been shown to carry 
antigens acquired from the intestinal lumen [86], and apoptotic enterocytes [87].  
These migrating cells are therefore in a unique position to transport prions from the 
gut. Andreoletti and colleagues have shown that in naturally infected sheep, PrPSc 
deposits are found in association with a population of CD68-positive cells in the dome 
area and B follicles of PP before being detected in FDCs [43]. CD68 is a macrophage 
marker but it is also expressed at low level on some DCs [88, 89]. By using thoracic 
duct cannulation of mesenteric lymphadenectomized rats, we have shown that 
intestinal DC but not T or B lymphocytes could indeed acquire PrPSc from the 
intestinal lumen and transport them in lymph towards the mesenteric nodes within 
hours of oral infection (Fig.1) [90].  
 
It is yet to be determined if DCs acquire PrPSc after it has been internalised by M 
cells, or by direct uptake across the mucosal epithelium, as recently shown for the 
transport of apoptotic intestinal epithelial cells [87] and bacteria [91]. At least some 
DCs are known to leave PP and arrive in mesenteric nodes, and Szakal and Tew have 
previously shown a cell population in the cortex of lymph nodes which can transport 
immune complexes from the subcapsular sinus, where DCs are frequently found, to 
FDCs [92]. Whether and how DCs release prions for uptake by FDCs remains 
unknown, but DCs can release intact antigen in vivo for recognition by B cells . 
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Release of cellular contents after cell death (DCs normally die within 3 days after 
reaching lymph nodes) is another possibility. It is of course also possible that oral 
TSE agents, once transported to ileal PP, probably via M cells, can reach and replicate 
on FDCs in situ, subsequently travelling to the CNS via enteric nerve endings [54, 93-
95]. However we have shown that they can also travel quickly to mesenteric nodes by 
hijacking intestinal DCs as a Trojan horse [90].  
 
6. Natural barriers for oral prion entry?  
 
In the experiment described above in which we could show PrPSc in DCs after 
intestinal delivery, we were unable to show that they contained infective material 
[90]. This probably reflects the sensitivity of the assay given that only a small number 
of cells could be injected into each mouse used in the assay, and of those DCs 
injected, only a small proportion (usually 0.5-5%) had acquired detectable amounts of 
PrPSc. A rough estimate suggests that only about one in ten thousand molecules given 
intestinally can be recovered from the DCs travelling in the thoracic duct lymph over 
a period of 16 hours. The efficiency of oral infection in animal models is generally 
very low in that ten times as much agent needs to be given orally compared to direct 
intra-cerebral inoculation [10]. Aucouturier and colleagues have demonstrated, using 
RAG knockout mice, that infected CD11c+ splenic dendritic cells (conventional DCs) 
alone, injected systemically (i.v.), are sufficient for prion propagation and 
transmission to the CNS [96]. The mice developed clinical disease without 
accumulation of prions in the spleen. This implies that CD11c+ dendritic cells can 
transport prions from the periphery to the CNS by a route not involving any additional 
lymphoid element.  
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An alternative explanation for the low efficiency of oral infection is that there may 
exist strong natural barriers for the pathogen in the gut, including possibly the gastric-
intestinal enzymes, and the cellular enzymatic activities in DCs. -As shown in Figure 
1, the PrPSc detected in the DC lysate appears to have been modified in some way and 
the characteristic three-band molecular signature after PK-treatment is not seen. This 
may be due, at least in part, to antigen processing in the DCs, since we have also 
demonstrated in vitro uptake of prion proteins by DCs leads to denaturation of the 
protein, followed by a time-dependent reduction in PrPSc detectable by 
immunoblotting (Fig.2) [90, 97]. This might sound surprising, as PrPSc is widely 
regarded as a protease-resistant molecule. The PrPSc fingerprints that identify prion 
strains are judged by the resistance of PrPSc to Protease K (PK), although its relative 
resistance to other proteases such as trypsin has also been demonstrated [98]. PK is 
however a fungal enzyme extracted from a mould (Tritirachium alnum). The enzymes 
in the cellular compartment and particularly gastro-intestinal tract are complex and 
identification of those responsible for PrPSc degradation may be of therapeutic 
significance.  It is also essential of course to determine whether the reduced immuno-
reactivity detected in DCs also correlates with diminished infectivity as previously 
reported for macrophages [99, 100]. 
 
These findings suggest that apart from the physical barrier formed by intestinal 
epithelium mentioned above, intracellular and possibly gastric-intestinal enzymes 
may be able to degrade prions – providing a natural barrier for prion entry that seems 
to have been largely overlooked previously. This barrier may explain the relative 
inefficiency often observed for oral/intragastric inoculation with TSE agents [10]. It 
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may also explain why despite many people in the UK consuming infected beef only a 
very limited number of people have so far developed nvCJD and why a decline in 
nvCJD cases [101] rather than an epidemic as previously predicted [102, 103] appears 
to be the current trend. Nevertheless, whereas transmission of BSE to human (causing 
nvCJD), and of scrapie to laboratory animals, via the oral route seems to have been 
relatively inefficient, transmission of BSE to cattle appears to have occurred much 
more readily, as this was the mode of transmission that led to the epidemic of BSE. 
Furthermore, as mentioned above, splenic PrPSc accumulation or replication does not 
appear to be necessary in the BSE-cattle transmission. An interesting and important 
question one may ask is therefore does this imply that cattle are somehow lacking in 
such degradative enzymes. 
 
7. Inflammation - “danger” in another way? 
 
The conclusion to be drawn from above findings is that the transmission of prion 
disease, especially via the oral route, may depend critically on a balance between 
clearance and propagation of the agent in the host. The normal intestinal immune 
system displays a balance in which pro-inflammatory and anti-inflammatory cells and 
molecules are carefully regulated to promote immunity against harmful invading 
pathogens while avoiding responses to self tissues and harmless dietary components 
[104]. The lack of inflammatory response in oral TSE infection may prevent the 
activation of macrophages whose phagocytic, enzymatic as well as phago-lysosomal 
fusion activities can be up-regulated by inflammation, speeding up the clearance 
process of the agent. It has been shown recently that the prion protein fragment 106-
126 is a chemoattractant for monocyte-derived immature but not mature DCs [105, 
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106], and on which the receptor has also been identified [105]. This might mean that 
the initial migration of immature DCs towards PrPSc can be regulated by the agent 
itself in the absence of overt inflammation. On the other hand the prion fragment can 
also enhance subsequent monocyte production of proinflammatory cytokines [105]. 
Inflammation stimulates the migration and maturation of DCs, which facilitates the 
transport of prion, and it is known that antigen processing is down-regulated in mature 
DC. The effects of inflammation may therefore alter the balance of prion uptake, 
retention and transport by DCs in several different ways, depending possibly on the 
stages of their transmission, DC maturation, and perhaps selectivity in the 
inflammatory mediators involved. It would make sense that the observed effects of 
immunosuppressive drugs on TSE susceptibility [36] could be due to their actions on 
the inflammatory machinery rather than the specific (B/T cells) immune system [107]. 
 
8. Therapeutic and preventive prospects 
 
As described above recent evidence has indicated a role of DCs in delivering and 
possibly propagating prions following oral inoculation. One should remember 
however that the main function of DC is to initiate immune responses. Prion-infected 
animals can develop normal immune responses, both humoral and cellular, to 
conventional antigens or mitogens [108, 109] but the absence of immune reaction to 
PrPSc is not surprising as it differs from the PrPC molecule only in tertiary structure. 
The fact that PrPC is a host-encoded protein and the immune system is presumably 
already tolerized to the molecule explains the lack of response.  
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However it is quite possible that although T cells are tolerized, B cells are not. This is 
because the mode of antigen recognition by T and B cells is quite distinct. T cells can 
recognize only processed antigen as peptides in the context of MHC molecules. Since 
PrPSc and PrPC share the primary structure (amino acid sequence, Diagram A), in 
theory, no T cell response would be expected, as reactive T cells would have been 
deleted in the thymus or tolerized in the periphery. However, the conformational 
changes of the protein may create new (foreign) epitopes (Diagram B) for B cells, 
which recognize native, unprocessed antigen. This implies that a B cell response may 
be potentially inducible providing that alternative T cell help can be offered. 
Encouraging findings have recently suggested a role for anti-prion molecules in 
disease prevention in a transgenic (mu chain anti-PrP) mouse model (Prnp knockout) 
[110]. This could provide an opportunity and rationale for novel therapeutic strategies 
in vaccine design by delivery of synthetic peptides with purpose-built T cell epitopes 
(Diagram C) attached to known B cell epitopes [111] leading to T-B, or DC-T-B (see 
below and Diagram D), collaborative responses. Efforts to identify such new B and T 
cell epitopes will rely on a good understanding of the 3-D structure not only for PrPC 
[112] but, more importantly, for PrPSc , yet to be obtained. 
 
Finally, DCs are a heterogeneous population of cells. DCs with immunogenic and 
tolerogenic properties have been shown in human and a variety of animal models 
[113, 114]. In addition some DC subpopulations can retain intact antigen more 
efficiently than others. Identification and characterization of particular DC subsets 
that are responsible for transmitting the disease, that are mediating immunity against 
the causal agents, and their responses to inflammatory stimuli may also prove to be 
informative. Although the transport of prions by DC is an early event of the infection 
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and hence is not likely to be a suitable site for intervention, potential therapeutic 
approaches may still be focused on how specific immunity to the agents can be 
effectively induced. These professional APC can be employed as a vector to deliver 
the ‘modeled vaccine’ mentioned above (Diagram D). In summary, a better 
understanding of all these aspects in prion pathogenesis could lead to rational 
immuno-manipulation strategies aimed at preventing the replication and spread of the 
infectious agents to the CNS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18 
 
 
References: 
1 J. K. Kirkwood, G. A. Wells, J. W. Wilesmith, A. A. Cunningham and S. I. 
Jackson, Spongiform encephalopathy in an arabian oryx (Oryx leucoryx) and a greater 
kudu (Tragelaphus strepsiceros) [see comments], Vet Rec 127 (1990) 418-420. 
 
2 J. M. Wyatt, G. R. Pearson, T. N. Smerdon, T. J. Gruffydd Jones, G. A. Wells 
and J. W. Wilesmith, Naturally occurring scrapie-like spongiform 
encephalopathy in five domestic cats [see comments], Vet Rec 129 (1991) 
233-236. 
 
3 I. H. Pattison, M. N. Hoare, J. N. Jebbett and W. A. Watson, Spread of scrapie 
to sheep and goats by oral dosing with foetal membranes from scrapie-affected 
sheep, Vet Rec 90 (1972) 465-468. 
 
4 M. Alpers and D. C. Gajdusek, Changing patterns of kuru: epidemiological 
changes in the period of increasing contact of the Fore people with western 
civilization, Am J Trop Med Hyg 14 (1965) 852-879. 
 
5 R. F. Marsh, R. A. Bessen, S. Lehmann and G. R. Hartsough, Epidemiological 
and experimental studies on a new incident of transmissible mink 
encephalopathy, J Gen Virol 72 (1991) 589-594. 
 
 19 
6 R. G. Will, J. W. Ironside, M. Zeidler, S. N. Cousens, K. Estibeiro, A. 
Alperovitch, et al., A new variant of Creutzfeldt-Jakob disease in the UK [see 
comments], Lancet 347 (1996) 921-925. 
 
7 J. D. Foster, J. Hope and H. Fraser, Transmission of bovine spongiform 
encephalopathy to sheep and goats, Vet Rec 133 (1993) 339-341. 
 
8 G. A. Wells, M. Dawson, S. A. Hawkins, R. B. Green, I. Dexter, M. E. 
Francis, et al., Infectivity in the ileum of cattle challenged orally with bovine 
spongiform encephalopathy, Vet Rec 135 (1994) 40-41. 
 
9 R. H. Kimberlin and C. A. Walker, Pathogenesis of scrapie in mice after 
intragastric infection, Virus Res 12 (1989) 213-220. 
 
10 S. B. Prusiner, S. P. Cochran and M. P. Alpers, Transmission of scrapie in 
hamsters, J Infect Dis 152 (1985) 971-978. 
 
11 J. W. Wilesmith, G. A. Wells, M. P. Cranwell and J. B. Ryan, Bovine 
spongiform encephalopathy: epidemiological studies, Vet Rec 123 (1988) 
638-644. 
 
12 C. A. Donnelly, N. M. Ferguson, A. C. Ghani and R. M. Anderson, 
Implications of BSE infection screening data for the scale of the British BSE 
epidemic and current European infection levels, Proc R Soc Lond B Biol Sci 
269 (2002) 2179-2190. 
 20 
 
13 W. Verbeke, Consumer reactions and economic consequences of the BSE 
crisis, Verh K Acad Geneeskd Belg 63 (2001) 483-492. 
 
14 J. Watts, TOKYO Japan's government tries to allay BSE fears, Lancet 358 
(2001) 2057. 
 
15 S. C. MacDiarmid, Bovine spongiform encephalopathy (BSE) in sheep?, Aust 
Vet J 80 (2002) 148-149. 
 
16 T. Alper, W. A. Cramp, D. A. Haig and M. C. Clarke, Does the agent of 
scrapie replicate without nucleic acid?, Nature 214 (1967) 764-766. 
 
17 D. C. Gajdusek, Unconventional viruses and the origin and disappearance of 
kuru, Science 197 (1977) 943-960. 
 
18 H. Narang, A critical review of the nature of the spongiform encephalopathy 
agent: protein theory versus virus theory, Exp Biol Med (Maywood) 227 
(2002) 4-19. 
 
19 D. D. Porter, H. G. Porter and N. A. Cox, Failure to demonstrate a humoral 
immune response to scrapie infection in mice, J Immunol 111 (1973) 1407-
1410. 
 
 21 
20 R. I. Carp, R. J. Kascsak, H. M. Wisniewski, P. A. Merz, R. Rubenstein, P. 
Bendheim, et al., The nature of the unconventional slow infection agents 
remains a puzzle, Alzheimer Dis Assoc Disord 3 (1989) 79-99. 
 
21 C. Weissmann, M. Enari, P. C. Klohn, D. Rossi and E. Flechsig, Transmission 
of prions, Proc Natl Acad Sci U S A 99 Suppl 4 (2002) 16378-16383. 
 
22 C. F. Farquhar, R. A. Somerville and M. E. Bruce, Straining the prion 
hypothesis [letter; comment], Nature 391 (1998) 345-346. 
 
23 S. B. Prusiner, D. C. Bolton, D. F. Groth, K. A. Bowman, S. P. Cochran and 
M. P. McKinley, Further purification and characterization of scrapie prions, 
Biochemistry 21 (1982) 6942-6950. 
 
24 G. S. Jackson and A. R. Clarke, Mammalian prion proteins, Curr Opin Struct 
Biol 10 (2000) 69-74. 
 
25 B. Oesch, D. Westaway, M. Walchli, M. P. McKinley, S. B. Kent, R. 
Aebersold, et al., A cellular gene encodes scrapie PrP 27-30 protein, Cell 40 
(1985) 735-746. 
 
26 S. B. Prusiner, Prions, Proc Natl Acad Sci U S A 95 (1998) 13363-13383. 
 
27 S. B. Prusiner, M. R. Scott, S. J. DeArmond and F. E. Cohen, Prion protein 
biology, Cell 93 (1998) 337-348. 
 22 
 
28 J. S. Griffith, Self-replication and scrapie, Nature 215 (1967) 1043-1044. 
 
29 S. B. Prusiner, Scrapie prions, Annu Rev Microbiol 43 (1989) 345-374. 
 
30 H. Bueler, A. Aguzzi, A. Sailer, R. A. Greiner, P. Autenried, M. Aguet, et al., 
Mice devoid of PrP are resistant to scrapie, Cell 73 (1993) 1339-1347. 
 
31 P. Aucouturier and C. Carnaud, The immune system and prion diseases: a 
relationship of complicity and blindness, J Leukoc Biol 72 (2002) 1075-1083. 
 
32 H. Fraser and A. G. Dickinson, Pathogenesis of scrapie in the mouse: the role 
of the spleen, Nature 226 (1970) 462-463. 
 
33 H. Fraser and A. G. Dickinson, Studies of the lymphoreticular system in the 
pathogenesis of scrapie: the role of spleen and thymus, J Comp Pathol 88 
(1978) 563-573. 
 
34 A. G. Dickinson and H. Fraser, Genetical control of the concentration of ME7 
scrapie agent in mouse spleen, J Comp Pathol 79 (1969) 363-366. 
 
35 C. I. Lasmezas, J. Y. Cesbron, J. P. Deslys, R. Demaimay, K. T. Adjou, R. 
Rioux, et al., Immune system-dependent and -independent replication of the 
scrapie agent, J Virol 70 (1996) 1292-1295. 
 
 23 
36 G. W. Outram, A. G. Dickinson and H. Fraser, Reduced susceptibility to 
scrapie in mice after steroid administration, Nature 249 (1974) 855-856. 
 
37 A. G. Dickinson, H. Fraser, I. McConnell and G. W. Outram, Mitogenic 
stimulation of the host enhances susceptibility to scrapie, Nature 272 (1978) 
54-55. 
 
38 C. M. Eklund, R. C. Kennedy and W. J. Hadlow, Pathogenesis of scrapie virus 
infection in the mouse, J Infect Dis 117 (1967) 15-22. 
 
39 R. H. Kimberlin and C. A. Walker, Pathogenesis of mouse scrapie: dynamics 
of agent replication in spleen, spinal cord and brain after infection by different 
routes, J Comp Pathol 89 (1979) 551-562. 
 
40 D. A. Hilton, E. Fathers, P. Edwards, J. W. Ironside and J. Zajicek, Prion 
immunoreactivity in appendix before clinical onset of variant Creutzfeldt-
Jakob disease [letter], Lancet 352 (1998) 703-704. 
 
41 L. J. van Keulen, B. E. Schreuder, R. H. Meloen, G. Mooij-Harkes, M. E. 
Vromans and J. P. Langeveld, Immunohistochemical detection of prion 
protein in lymphoid tissues of sheep with natural scrapie, J Clin Microbiol 34 
(1996) 1228-1231. 
 
42 R. Heggebo, C. M. Press, G. Gunnes, K. I. Lie, M. A. Tranulis, M. Ulvund, et 
al., Distribution of prion protein in the ileal Peyer's patch of scrapie- free 
 24 
lambs and lambs naturally and experimentally exposed to the scrapie agent, J 
Gen Virol 81 (2000) 2327-2337. 
 
43 O. Andreoletti, P. Berthon, D. Marc, P. Sarradin, J. Grosclaude, L. van 
Keulen, et al., Early accumulation of PrP(Sc) in gut-associated lymphoid and 
nervous tissues of susceptible sheep from a Romanov flock with natural 
scrapie, J Gen Virol 81 (2000) 3115-3126. 
 
44 R. Heggebo, C. M. Press, G. Gunnes, L. Gonzalez and M. Jeffrey, Distribution 
and accumulation of PrP in gut-associated and peripheral lymphoid tissue of 
scrapie-affected Suffolk sheep, J Gen Virol 83 (2002) 479-489. 
 
45 R. A. Somerville, C. R. Birkett, C. F. Farquhar, N. Hunter, W. Goldmann, J. 
Dornan, et al., Immunodetection of PrPSc in spleens of some scrapie-infected 
sheep but not BSE-infected cows, J Gen Virol 78 (1997) 2389-2396. 
 
46 T. Maignien, C. I. Lasmezas, V. Beringue, D. Dormont and J. P. Deslys, 
Pathogenesis of the oral route of infection of mice with scrapie and bovine 
spongiform encephalopathy agents, J Gen Virol 80 (1999) 3035-3042. 
 
47 J. D. Foster, D. W. Parnham, N. Hunter and M. Bruce, Distribution of the 
prion protein in sheep terminally affected with BSE following experimental 
oral transmission, J Gen Virol 82 (2001) 2319-2326. 
 
 25 
48 P. S. Kaeser, M. A. Klein, P. Schwarz and A. Aguzzi, Efficient 
lymphoreticular prion propagation requires PrP(c) in stromal and 
hematopoietic cells, J Virol 75 (2001) 7097-7106. 
 
49 M. C. Clarke and R. H. Kimberlin, Pathogenesis of mouse scrapie: distribution 
of agent in the pulp and stroma of infected spleens, Vet Microbiol 9 (1984) 
215-225. 
 
50 H. Fraser and C. F. Farquhar, Ionising radiation has no influence on scrapie 
incubation period in mice, Vet Microbiol 13 (1987) 211-223. 
 
51 P. A. McBride, P. Eikelenboom, G. Kraal, H. Fraser and M. E. Bruce, PrP 
protein is associated with follicular dendritic cells of spleens and lymph nodes 
in uninfected and scrapie-infected mice, J Pathol 168 (1992) 413-418. 
 
52 T. Kitamoto, T. Muramoto, S. Mohri, K. Doh Ura and J. Tateishi, Abnormal 
isoform of prion protein accumulates in follicular dendritic cells in mice with 
Creutzfeldt-Jakob disease, J Virol 65 (1991) 6292-6295. 
 
53 A. F. Hill, R. J. Butterworth, S. Joiner, G. Jackson, M. N. Rossor, D. J. 
Thomas, et al., Investigation of variant Creutzfeldt-Jakob disease and other 
human prion diseases with tonsil biopsy samples, Lancet 353 (1999) 183-189. 
 
 26 
54 M. Beekes and P. A. McBride, Early accumulation of pathological PrP in the 
enteric nervous system and gut-associated lymphoid tissue of hamsters orally 
infected with scrapie, Neurosci Lett 278 (2000) 181-184. 
 
55 M. Jeffrey, G. McGovern, C. M. Goodsir, K. L. Brown and M. E. Bruce, Sites 
of prion protein accumulation in scrapie-infected mouse spleen revealed by 
immuno-electron microscopy, J Pathol 191 (2000) 323-332. 
 
56 N. A. Mabbott, M. E. Bruce, M. Botto, M. J. Walport and M. B. Pepys, 
Temporary depletion of complement component C3 or genetic deficiency of 
C1q significantly delays onset of scrapie, Nat Med 7 (2001) 485-487. 
 
57 M. A. Klein, P. S. Kaeser, P. Schwarz, H. Weyd, I. Xenarios, R. M. 
Zinkernagel, et al., Complement facilitates early prion pathogenesis, Nat Med 
7 (2001) 488-492. 
 
58 P. Joling, L. J. Bakker, J. A. Van Strijp, T. Meerloo, L. de Graaf, M. E. 
Dekker, et al., Binding of human immunodeficiency virus type-1 to follicular 
dendritic cells in vitro is complement dependent, J Immunol 150 (1993) 1065-
1073. 
 
59 K. Kaneko, D. Peretz, K. M. Pan, T. C. Blochberger, H. Wille, R. Gabizon, et 
al., Prion protein (PrP) synthetic peptides induce cellular PrP to acquire 
properties of the scrapie isoform, Proc Natl Acad Sci U S A 92 (1995) 11160-
11164. 
 27 
 
60 M. A. Klein, R. Frigg, A. J. Raeber, E. Flechsig, I. Hegyi, R. M. Zinkernagel, 
et al., PrP expression in B lymphocytes is not required for prion 
neuroinvasion, Nat Med 4 (1998) 1429-1433. 
 
61 L. Manuelidis, I. Zaitsev, P. Koni, Z. Y. Lu, R. A. Flavell and W. Fritch, 
Follicular dendritic cells and dissemination of Creutzfeldt-Jakob disease, J 
Virol 74 (2000) 8614-8622. 
 
62 M. A. Klein, R. Frigg, E. Flechsig, A. J. Raeber, U. Kalinke, H. Bluethmann, 
et al., A crucial role for B cells in neuroinvasive scrapie [see comments], 
Nature 390 (1997) 687-690. 
 
63 Z. F. Kapasi, G. F. Burton, L. D. Shultz, J. G. Tew and A. K. Szakal, 
Induction of functional follicular dendritic cell development in severe 
combined immunodeficiency mice. Influence of B and T cells, J Immunol 150 
(1993) 2648-2658. 
 
64 N. A. Mabbott, J. Young, I. McConnell and M. E. Bruce, Follicular dendritic 
cell dedifferentiation by treatment with an inhibitor of the lymphotoxin 
pathway dramatically reduces scrapie susceptibility, J Virol 77 (2003) 6845-
6854. 
 
 28 
65 K. L. Brown, K. Stewart, D. L. Ritchie, N. A. Mabbott, A. Williams, H. 
Fraser, et al., Scrapie replication in lymphoid tissues depends on prion protein- 
expressing follicular dendritic cells, Nat Med 5 (1999) 1308-1312. 
 
66 J. L. Wolf and W. A. Bye, The membranous epithelial (M) cell and the 
mucosal immune system, Annu Rev Med 35 (1984) 95-112. 
 
67 J. L. Wolf, R. Dambrauskas, A. H. Sharpe and J. S. Trier, Adherence to and 
penetration of the intestinal epithelium by reovirus type 1 in neonatal mice, 
Gastroenterology 92 (1987) 82-91. 
 
68 B. D. Jones, N. Ghori and S. Falkow, Salmonella typhimurium initiates 
murine infection by penetrating and destroying the specialized epithelial M 
cells of the Peyer's patches, J. Exp. Med. (1994) 15-23. 
 
69 R. L. Owen, N. F. Pierce, R. T. Apple and W. C. Cray, Jr., M cell transport of 
Vibrio cholerae from the intestinal lumen into Peyer's patches: a mechanism 
for antigen sampling and for microbial transepithelial migration, J Infect Dis 
153 (1986) 1108-1118. 
 
70 R. I. Walker, E. A. Schmauder Chock, J. L. Parker and D. Burr, Selective 
association and transport of Campylobacter jejuni through M cells of rabbit 
Peyer's patches, Can J Microbiol 34 (1988) 1142-1147. 
 
 29 
71 L. R. Inman and J. R. Cantey, Peyer's patch lymphoid follicle epithelial 
adherence of a rabbit enteropathogenic Escherichia coli (strain RDEC-1). Role 
of plasmid-mediated pili in initial adherence, J Clin Invest 74 (1984) 90-95. 
 
72 M. Regoli, C. Borghesi, E. Bertelli and C. Nicoletti, Uptake of a gram-positive 
bacterium (Streptococcus pneumoniae R36a) by the M cells of rabbit Peyer's 
patches, Anat Anz 177 (1995) 119-124. 
 
73 R. M. Steinman, D. S. Lustig and Z. A. Cohn, Identification of a novel cell 
type in peripheral lymphoid organs of  mice. III Functional properties in vivo, 
J. Exp. Med. 139 (1974) 1431-1435. 
 
74 M. S. Sy and P. Gambetti, Prion replication-once again blaming the dendritic 
cell, Nat Med 5 (1999) 1235-1237. 
 
75 G. J. Thorbecke, A. R. Amin and V. K. Tsiagbe, Biology of germinal centers 
in lymphoid tissue, Faseb Journal 8 (1994) 832-840. 
 
76 C. Reis e Sousa, P. D. Stahl and J. M. Austyn, Phagocytosis of antigens by 
Langerhans cells in vitro, J Exp Med 178 (1993) 509-519. 
 
77 F. Sallusto, M. Cella, C. Danieli and A. Lanzavecchia, Dendritic cells use 
macropinocytosis and the mannose receptor to concentrate macromolecules in 
the major histocompatibility complex class II compartment: downregulation 
 30 
by cytokines and bacterial products [see comments], J Exp Med 182 (1995) 
389-400. 
 
78 R. M. Steinman, The dendritic cell system and its role in immunogenicity, 
Annu Rev Immunol 9 (1991) 271-296. 
 
79 G. G. MacPherson, N. Kushnir and M. Wykes, Dendritic cells, B cells and the 
regulation of antibody synthesis, Immunol. Rev. 172 (1999) 325-334. 
 
80 J. Burthem, B. Urban, A. Pain and D. J. Roberts, The normal cellular prion 
protein is strongly expressed by myeloid dendritic cells, Blood 98 (2001) 
3733-3738. 
 
81 M. Sugaya, K. Nakamura, T. Watanabe, A. Asahina, N. Yasaka, Y. Koyama, 
et al., Expression of cellular prion-related protein by murine Langerhans cells 
and keratinocytes, J Dermatol Sci 28 (2002) 126-134. 
 
82 D. A. Hume, D. Halpin, H. Charlton and S. Gordon, The mononuclear 
phagocyte system of the mouse defined by immunohistochemical localisation 
of antigen F4/80 :  Macrophages of endocrine organs., Proc Natl Acad Sci 81 
(1984) 4171. 
 
83 B. L. Kelsall and W. Strober, Distinct populations of dendritic cells are present 
in the subepithelial dome and T cell regions of the murine Peyer's patch, J Exp 
Med 183 (1996) 237-247. 
 31 
 
84 I. Maric, P. G. Holt, M. H. Perdue and J. Bienenstock, Class II MHC antigen 
(Ia)-bearing dendritic cells in the epithelium of the rat intestine, J Immunol 
156 (1996) 1408-1414. 
 
85 S. Gordon, S. Keshav and L. P. Chung, Mononuclear phagocytes: Tissue 
distribution and functional heterogeneity, Current Opinion in Immunology 1 
(1988) 26-35. 
 
86 L. M. Liu and G. G. MacPherson, Antigen acquisition by dendritic cells: 
intestinal dendritic cells acquire antigen administered orally and can prime 
naive T cells in vivo, J. Exp. Med. 177 (1993) 1299-1307. 
 
87 F. P. Huang, N. Platt, M. Wykes, J. R. Major, T. J. Powell, C. D. Jenkins, et 
al., A discrete subpopulation of dendritic cells transports apoptotic intestinal 
epithelial cells to T cell areas of mesenteric lymph nodes, J. Exp. Med. 191 
(2000) 435-444. 
 
88 M. G. Betjes, M. C. Haks, C. W. Tuk and R. H. Beelen, Monoclonal antibody 
EBM11 (anti-CD68) discriminates between dendritic cells and macrophages 
after short-term culture, Immunobiology 183 (1991) 79-87. 
 
89 H. Strobl, C. Scheinecker, E. Riedl, B. Csmarits, C. Bello-Fernandez, W. F. 
Pickl, et al., Identification of CD68+lin- peripheral blood cells with dendritic 
precursor characteristics, J Immunol 161 (1998) 740-748. 
 32 
 
90 F. P. Huang, C. F. Farquhar, N. A. Mabbott, M. E. Bruce and G. G. 
MacPherson, Migrating intestinal dendritic cells transport PrP(Sc) from the 
gut, J Gen Virol 83 (2002) 267-271. 
 
91 M. Rescigno, M. Urbano, B. Valzasina, M. Francolini, G. Rotta, R. Bonasio, 
et al., Dendritic cells express tight junction proteins and penetrate gut 
epithelial monolayers to sample bacteria, Nat Immunol 2 (2001) 361-367. 
 
92 A. L. Szakal, K. L. Holmes and J. G. Tew, Transport of immune complexes 
from the subcapsular sinus to lymph node follicles on the surface of non-
phagocytic cells, including cells with dendritic morphology., J Immuno 131 
(1983) 1714. 
 
93 P. A. McBride and M. Beekes, Pathological PrP is abundant in sympathetic 
and sensory ganglia of hamsters fed with scrapie, Neurosci Lett 265 (1999) 
135-138. 
 
94 A. N. Shmakov, N. F. McLennan, P. McBride, C. F. Farquhar, J. Bode, K. A. 
Rennison, et al., Cellular prion protein is expressed in the human enteric 
nervous system, Nat Med 6 (2000) 840-841. 
 
95 C. J. Sigurdson, T. R. Spraker, M. W. Miller, B. Oesch and E. A. Hoover, 
PrP(CWD) in the myenteric plexus, vagosympathetic trunk and endocrine 
glands of deer with chronic wasting disease, J Gen Virol 82 (2001) 2327-2334. 
 33 
 
96 P. Aucouturier, F. Geissmann, D. Damotte, G. P. Saborio, H. C. Meeker, R. 
Kascsak, et al., Infected splenic dendritic cells are sufficient for prion 
transmission to the CNS in mouse scrapie, J Clin Invest 108 (2001) 703-708. 
 
97 K. M. Luhr, R. P. Wallin, H. G. Ljunggren, P. Low, A. Taraboulos and K. 
Kristensson, Processing and degradation of exogenous prion protein by 
CD11c(+) myeloid dendritic cells in vitro, J Virol 76 (2002) 12259-12264. 
 
98 M. P. McKinley, D. C. Bolton and S. B. Prusiner, A protease-resistant protein 
is a structural componenet of the scrapie, Cell 35 (1983) 57-62. 
 
99 R. I. Carp and S. M. Callahan, Effect of mouse peritoneal macrophages on 
scrapie infectivity during extended in vitro incubation, Intervirology 17 (1982) 
201-207. 
 
100 V. Beringue, M. Demoy, C. I. Lasmezas, B. Gouritin, C. Weingarten, J. P. 
Deslys, et al., Role of spleen macrophages in the clearance of scrapie agent 
early in pathogenesis, J Pathol 190 (2000) 495-502. 
 
101 A. C. Ghani, C. A. Donnelly, N. M. Ferguson and R. M. Anderson, Updated 
projections of future vCJD deaths in the UK, BMC Infect Dis 3 (2003) 4. 
 
102 S. N. Cousens, E. Vynnycky, M. Zeidler, R. G. Will and P. G. Smith, 
Predicting the CJD epidemic in humans, Nature 385 (1997) 197-198. 
 34 
 
103 P. G. Smith, The epidemics of bovine spongiform encephalopathy and variant 
Creutzfeldt-Jakob disease: current status and future prospects, Bull World 
Health Organ 81 (2003) 123-130. 
 
104 R. P. MacDermott, Alterations of the mucosal immune system in 
inflammatory bowel disease, J Gastroenterol 31 (1996) 907-916. 
 
105 Y. Le, H. Yazawa, W. Gong, Z. Yu, V. J. Ferrans, P. M. Murphy, et al., The 
neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for 
the G protein-coupled receptor formyl peptide receptor-like 1, J Immunol 166 
(2001) 1448-1451. 
 
106 N. C. Kaneider, A. Kaser, S. Dunzendorfer, H. Tilg and C. J. Wiedermann, 
Sphingosine kinase-dependent migration of immature dendritic cells in 
response to neurotoxic prion protein fragment, J Virol 77 (2003) 5535-5539. 
 
107 G. W. Outram, A. G. Dickinson and H. Fraser, Slow encephalopathies, 
inflammatory responses and arachis oil, Lancet 1 (1975) 198-200. 
 
108 A. C. Gardiner and A. A. Marucci, Immunological responsiveness of scrapie 
infected mice, J Comp Pathol 79 (1969) 233-235. 
 
 35 
109 D. T. Kingsbury, D. A. Smeltzer, C. J. Gibbs, Jr. and D. C. Gajdusek, 
Evidence for normal cell-mediated immunity in scrapie-infected mice, Infect 
Immun 32 (1981) 1176-1180. 
 
110 F. L. Heppner, C. Musahl, I. Arrighi, M. A. Klein, T. Rulicke, B. Oesch, et al., 
Prevention of scrapie pathogenesis by transgenic expression of anti- prion 
protein antibodies, Science 294 (2001) 178-182. 
 
111 L. E. Soto Ramirez, B. Renjifo, M. F. McLane, R. Marlink, O. H. C, R. 
Sutthent, et al., HIV-1 Langerhans' cell tropism associated with heterosexual 
transmission of HIV, Science 271 (1996) 1291-1293. 
 
112 K. J. Knaus, M. Morillas, W. Swietnicki, M. Malone, W. K. Surewicz and V. 
C. Yee, Crystal structure of the human prion protein reveals a mechanism for 
oligomerization, Nat Struct Biol 8 (2001) 770-774. 
 
113 R. M. Steinman, D. Hawiger and M. C. Nussenzweig, Tolerogenic dendritic 
cells, Annu Rev Immunol 21 (2003) 685-711. 
 
114 F. P. Huang and G. G. MacPherson, Continuing Education of the Immune 
System - Dendritic Cells, Immune Regulation and Tolerance, Current 
Molecular Medicine 1 (2001) 457-468. 
 
 36 
Table 1: Dendritic cells and follicular dendritic cells are distinctive cell types 
 
Cell:  Follicular dendritic cell  Dendritic cell 
 
Ontogeny: Obscure, non-haemopoietic  Bone marrow-derived, haemopoietic 
 
Distribution: Secondary lymphoid organs  Peripheral tissues, secondary   
(B cell follicles)   lymphoid organs (T cell areas) 
 
Life-span: Long (years)    Short (days - not Langerhans cells) 
 
Functions: Antigen presentation (B cells -  Antigen presentation (peptides to T 
as immune complexes)   cells on MHC) 
 
Migration: Non-migratory, resident  Actively migratory 
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Figure Legends 
Figure 1.  Intestinal DCs transport PrPSc to mesenteric nodes via lymph. Lymph 
was collected 8 to 16 h after intestinal injection of mouse scrapie-associated fibrils 
(ME7 SAF). Conspicuous PrP+ cytoplasmic inclusions were detected by 
immunocytochemistry in a small proportion of DCs (a) but not B (b) or T (c) 
lymphocytes in the thoracic duct lymph of mesenteric lymphadenectomized rats. (d) 
Control DCs from PBS-injected animals. Magnification x1000.  
(e) Immunoblot analysis of pooled cell lysates (1x106 cells per lane) from SAF-
treated rats confirmed the presence of PrPSc in lymph DCs (lane 4) but not in T or B 
lymphocytes. SAF equivalent to 2 or 4 µg of infected brain tissue was loaded in lanes 
5 and 6, respectively. Treatment of samples in the presence (+) or absence (-) of 
proteinase K (PK) before electrophoresis is indicated. In all panels, PrP was detected 
using the PrP-specific polyclonal antiserum 1B3. 
(Huang et al. JGV 2002; 83:267-271) 
 
Figure 2. DCs acquire and process PrPSc following in vitro culture with SAF. 
Bone marrow-derived DCs (BMDC, 1x106 cells) were cultured in the absence 
(BMDC alone) or presence of SAF (equivalent to 10 mg infected brain tissue) for the 
times indicated. Immunoblots show the accumulation of detergent-insoluble, 
relatively proteinase K-resistant PrPSc within BMDC lysates. Treatment of lysates in 
the presence (+) or absence (-) of proteinase K (Pk) is indicated. SAF was incubated 
in medium alone as a control. Following Pk treatment, a typical three-band pattern 
was observed between molecular mass values of 20 and 30 kDa, representing 
unglycosylated, monoglycosylated and diglycosylated isomers of PrP (in order of 
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increasing molecular mass). SAF equivalent to 50 µg infected brain tissue and/or 
BMDCs equivalent to 104 cells were loaded per lane. 
(Huang et al. JGV 2002; 83:267-271) 
 
Figure 3: Modeling T cell epitopes for inducing DC-T-B cell collaborative 
responses against PrPsc. Schematic representations of the primary sequence (A) and 
tertiary structure (B) of PrPsc, and the purpose-built synthetic new epitope for T cell 
recognition (C). Cellular interactions, antigen presentation and recognition by DC, B 
and T cells after encountering the natural B cell epitope (b d f) and the synthetic T 
(and B) cell epitope (b’d’f’) are depicted in (D).  
 
 
 



